NexImmune, Inc., a biopharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on August 27, 2024, to deregister any unsold securities under its previous Registration Statement No. 333-263399. This move follows the stockholders' approval of the company's dissolution, liquidation, and winding-up, as disclosed in a Form 8-K filed on August 15, 2024. The company has ceased all offerings of its securities in accordance with the Plan of Liquidation and Dissolution. The President of NexImmune, Craig Jalbert, signed the amendment, which officially terminates the effectiveness of the registration statement and withdraws all unsold securities from registration.

NexImmune, Inc., a biopharmaceutical company, has filed a post-effective amendment with the Securities and Exchange Commission (SEC) on August 27, 2024, to deregister any unsold securities under its previous Registration Statement No. 333-263399. This move follows the stockholders' approval of the company's dissolution, liquidation, and winding-up, as disclosed in a Form 8-K filed on August 15, 2024. The company has ceased all offerings of its securities in accordance with the Plan of Liquidation and Dissolution. The President of NexImmune, Craig Jalbert, signed the amendment, which officially terminates the effectiveness of the registration statement and withdraws all unsold securities from registration.